Skip to main content
HomeDrug Comparisons
Drug bottle and Pill

Compare Rybrevant vs. Tagrisso

Head-to-head comparisons of medication uses, side effects, warnings, and more.

  • Rybrevant (amivantamab)
    Tagrisso (osimertinib)
  • Rybrevant (amivantamab)
    Tagrisso (osimertinib)

  • Summary of Rybrevant vs. Tagrisso

    Summary for Bispecific EGF receptor-directed and MET receptor-directed antibody
    Prescription only

    Rybrevant (amivantamab-vmjw) is an injectable medication used for adults with non-small cell lung cancer (NSCLC) with certain mutations in the epidermal growth factor receptor (EGFR) gene. The medication is given as an intravenous infusion through your vein (IV), and how often you receive it depends on what you’re being treated for. You also might receive it with other cancer medications. Some common side effects of Rybrevant (amivantamab) include infusion-related reactions, rash, feeling tired, and infected skin around the nail.

    Summary for Epidermal Growth Factor Receptor (EGFR) inhibitor
    Prescription only

    Tagrisso (osimertinib) is taken by mouth to treat non-small cell lung cancer (NSCLC). It’s only used when the tumor has a specific change (mutation) in the EGFR gene, which can be detected with a certain test. It’s convenient to take because you take it by mouth, but it can have some side effects such as acne-like rash, diarrhea, and changes in heart rhythm.

  • Indications of Rybrevant vs. Tagrisso

    Indications for

    Adults with locally advanced or metastatic NSCLC with certain EGFR mutations:

    •In combination with lazertinib as a first-choice treatment
    •In combination with carboplatin and pemetrexed as a second-choice treatment for those whose condition has worsened or didn't respond well to EGFR tyrosine kinase inhibitor
    •In combination with carboplatin and pemetrexed as a first-choice treatment
    •Given alone for those whose condition has worsened or didn’t respond well to platinum-based chemotherapy
    Indications for
    •

    Metastatic NSCLC with specific EGFR mutations as initial treatment or in those no longer responding to other oral EGFR inhibitors

    •

    NSCLC with specific EGFR mutations (given after surgery to remove the entire tumor)

  • Pros and Cons of Rybrevant vs. Tagrisso

    Pros and Const for Bispecific EGF receptor-directed and MET receptor-directed antibody
    Pros
    •Recommended option for non-small cell lung cancer (NSCLC) in certain adults
    •Works in a more targeted way than traditional chemotherapy
    •Lasts a long time in the body, so it doesn’t need to be taken every day
    Cons
    •Commonly causes rash, infected skin around the nails, and serious infusion-related reactions
    •Needs to be infused through the vein at an infusion center or clinic
    •Long infusion times, especially for the first few treatments
    Pros and Const for Epidermal Growth Factor Receptor (EGFR) inhibitor
    Pros
    •Works in a more specific, targeted way than traditional chemotherapy
    •Works on certain cancers after other medications don’t work anymore
    •Taken by mouth, so good for people who don’t like needles
    Cons
    •Often causes an itchy, acne-like rash on the face and upper body
    •Not recommended during pregnancy or breastfeeding
    •Often causes diarrhea, but usually mild

  • Common Side Effects of Rybrevant vs. Tagrisso

    Common Side Effects for
    •Rash
    •Infected skin around the nail
    •Muscle and joint pain
    •Sores in the mouth
    •Swelling of hands, ankles, feet, face, or all of your body
    •Unusual feeling in the skin (such as tingling or a crawling feeling)
    •Feeling very tired
    •Diarrhea
    •Constipation
    •COVID-19
    •Dry skin
    •Bleeding
    •Decreased appetite
    •Itchy skin
    •Nausea
    •Changes in certain blood tests
    •Vomiting
    •Shortness of breath
    •Cough

    Note: The side effects listed above reflect reports from clinical studies where Rybrevant (amivantamab) was given alone or with other medications.

    Common Side Effects for
    •Low white blood cell count (up to 65%)
    •Low platelets (53%)
    •Low red blood cells (47%)
    •Diarrhea (47%)
    •Acne-like rash (45%)
    •Muscle aches/pain (36%)
    •Nail changes (33%)
    •Dry skin (32%)
    •Mouth blisters and pain (26%)
    •Fatigue (21%)
    •Cough (20%)

  • Warnings of Rybrevant vs. Tagrisso

    Common Side Effects for
    •Infusion-related reactions
    •Lung problems
    •Blood clots (if used in combination with lazertinib)
    •Skin problems
    •Eye problems
    •Harm to the unborn baby
    Common Side Effects for
    •Serious lung problems
    •Serious heart problems
    •Eye problems
    •Serious skin problems
    •Serious blood problems
    •Harm to unborn baby

  • Prices with our coupons for Rybrevant vs. Tagrisso

    Learn more about Rybrevant
    Learn more about Tagrisso

Compare other Lung Cancer drugs

Rybrevant vs TagrissoImfinzi vs KeytrudaJemperli vs KeytrudaKeytruda vs OpdivoKeytruda vs TecentriqLibtayo vs KeytrudaTagrisso vs Keytruda
View More

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.